EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsMichael T. McCabe, Caretha L. Creasy, Heidi M. Ott et al.|Nature|2012Cited by 1.8k
Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in CellsBruce Grasberger, Roger Bone, Eugene C. Petrella et al.|Journal of Medicinal Chemistry|2005Cited by 430
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2Sharad K. Verma, William H. Miller, Xinrong Tian et al.|ACS Medicinal Chemistry Letters|2012Cited by 377
Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation <i>in vitro</i> and sensitize tumors to doxorubicin <i>in vivo</i>Holly K. Koblish, Anna C. Maroney, Shuyuan Zhao et al.|Molecular Cancer Therapeutics|2006Cited by 164
Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3<i>S</i>)-3-piperidinylmethyl]oxy}-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT KinaseDirk A. Heerding, Rakesh Kumar, Nelson Rhodes et al.|Journal of Medicinal Chemistry|2008Cited by 158